In a previous pilot study of the FreeStyle Navigator™ Continuous Glucose Monitoring System (“Navigator”, Abbott Diabetes Care) in 30 children and adolescents with type 1 diabetes (T1D) using insulin pumps, we found that Navigator use averaged >130 hours per week over 13 weeks and mean HbA1c dropped from 7.1 ± 0.6% to 6.8 ± 0.7% (p=0.02) (1). The current study evaluated whether the Navigator was similarly tolerated over 13 weeks in 27 children aged 4–17 years with T1D using glargine-based multiple daily injection (MDI) insulin regimens. Subjects averaged >100 hours/week of Navigator use. Mean HbA1c fell from 7.9 ± 1.0% at baseline to 7.3 ± 0.9% at 13 weeks (p=0.004). High satisfaction with the Navigator was reported on the Continuous Glucose Monitor Satisfaction Scale. These encouraging pilot study results support the inclusion of MDI users in longer-term randomized clinical trials of continuous glucose monitors (CGM).